Randall Bateman

Affiliations: 
Neurology Washington University School of Medicine, St. Louis, MO, United States 
Google:
"Randall Bateman"
Mean distance: (not calculated yet)
 
BETA: Related publications

Publications

You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Galasko D, Farlow MR, Lucey BP, et al. (2024) A multicenter, randomized, double-blind, placebo-controlled ascending dose study to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamic (PD) effects of Posiphen in subjects with early Alzheimer's Disease. Alzheimer's Research & Therapy. 16: 151
Xiong C, Luo J, Wolk DA, et al. (2024) Baseline levels and longitudinal changes in plasma Aβ42/40 among Black and white individuals. Nature Communications. 15: 5539
Ibanez L, Liu M, Beric A, et al. (2024) Benchmarking of a multi-biomarker low-volume panel for Alzheimer's Disease and related dementia research. Medrxiv : the Preprint Server For Health Sciences
Iaccarino L, Llibre-Guerra JJ, McDade E, et al. (2024) Molecular neuroimaging in dominantly inherited versus sporadic early-onset Alzheimer's disease. Brain Communications. 6: fcae159
Wagemann O, Liu H, Wang G, et al. (2024) Downstream Biomarker Effects of Gantenerumab or Solanezumab in Dominantly Inherited Alzheimer Disease: The DIAN-TU-001 Randomized Clinical Trial. Jama Neurology
Levin J, Baiardi S, Quadalti C, et al. (2024) α-Synuclein seed amplification assay detects Lewy body co-pathology in autosomal dominant Alzheimer's disease late in the disease course and dependent on Lewy pathology burden. Alzheimer's & Dementia : the Journal of the Alzheimer's Association
Wisch JK, McKay NS, Boerwinkle AH, et al. (2024) Comparison of tau spread in people with Down syndrome versus autosomal-dominant Alzheimer's disease: a cross-sectional study. The Lancet. Neurology. 23: 500-510
Galasko D, Farlow MR, Lucey BP, et al. (2024) A multicenter, randomized, double-blind, placebo-controlled ascending dose study to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamic (PD) effects of Posiphen in subjects with Early Alzheimer's Disease. Medrxiv : the Preprint Server For Health Sciences
Doering S, McCullough A, Gordon BA, et al. (2024) Deconstructing pathological tau by biological process in early stages of Alzheimer disease: a method for quantifying tau spatial spread in neuroimaging. Ebiomedicine. 103: 105080
Canestaro WJ, Bateman RJ, Holtzman DM, et al. (2024) Use of a Blood Biomarker Test Improves Economic Utility in the Evaluation of Older Patients Presenting with Cognitive Impairment. Population Health Management
See more...